PKM and neoplasm: Interestingly, cytoplasmic PKM2 immunostaining intensity in non-regressing xenografts was lower (≤ 1+) in ~5% of the specimens and higher in nucleus (3+) in ≥ 75% than those seen in regressing tumor xenografts (P≤0.05; Fig 7B).